Category

Vascular BioSciences to Make Six Presentations at the American Thoracic Society in San Francisco from May 15 – May 18 Vascular BioSciences to present the full scope of its research efforts at this year’s ATS International ConferenceGoleta, CA, May 12, 2016 – Vascular BioSciences annou

Vascular BioSciences Named the 2015 Winner of the Buzz of Bio “Pipelines of Promise” Competition Goleta, CA, May 21, 2015 – On April 30, 2015, the Biotech International Organization (BIO) announced Vascular BioSciences (VBS) as the winner of its Buzz of BIO competition in the “P

The American Journal of Pathology Highlights “CAR Selectively Enhances Drug Efficacy in PAH” as a Featured Article in the February 2014 Issue Goleta, CA, February 5, 2014 – The American Journal of Pathology announced in a press release that a peer-reviewed scientific article about Vas

Vascular BioSciences Announces Online Publication of Scientific Article Describing First Orally Available Disease Homing Peptide That Can Selectively Enhance the Effects of Co-Administered Drugs Goleta, CA, January 6, 2014 – Vascular BioSciences announces the e-publication of “A

Vascular BioSciences Awarded $1.2 Million Contract from the NHLBI’s Vascular Interventions/Innovations and Therapeutic Advances (VITA) Program to Develop CAR Peptide Therapeutic Adjuvant for PAH Targeted Therapy Durham, NC – Vascular BioSciences (VBS) announced the award of a $1.2 mil

Vascular BioSciences announces publication of “Vascular Histomolecular Analysis By Sequential Endoarterial Biopsy in a Shunt Model of Pulmonary Hypertension” in the Current Issue of Pulmonary Circulation Goleta, CA., April 10, 2013 – Vascular BioSciences announces the publication of “

Vascular BioSciences recently awarded a NIH SBIR/STTR Phase I Commercialization Assistance Award to develop the CAR peptide as a therapeutic adjuvant. Goleta, CA., October 11, 2012 – Vascular BioSciences recently awarded a NIH SBIR/STTR Phase I Commercialization Assistance Award to de

Vascular BioSciences announces CEO David Mann will present “CAR Peptide, a Disease Selective Therapeutic Adjuvant For Targeted Drug Therapy” during the 7th Annual Therapeutic Peptide Symposium San Diego, CA., October 10, 2012 – Vascular BioSciences announces CEO David Mann will presen

Vascular BioSciences announced today that Dr. Kalju Kahn, PhD, has been named head of Medicinal Chemistry Goleta, Calif., July 3, 2012 – Vascular BioSciences announced today that Dr. Kalju Kahn, PhD, has been named head of Medicinal Chemistry. Dr. Kahn, an expert in computational chem

Vascular Biosciences announces publication of “Hemodynamic and Histologic Characterization of a Swine (Sus scrofa domestica) Model of Chronic Pulmonary Arterial Hypertension” Durnham, North Carolina, June 27, 2011 – Vascular BioSciences announces the publication of a scientific articl